

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5030099

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AKARI THERAPEUTICS, PLC	11/02/2016
RECEIVING PARTY DATA	
Name:	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Street Address:	P.O. BOX 39135
City:	JERUSALEM
State/Country:	ISRAEL
Postal Code:	91390
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14525111
CORRESPONDENCE DATA	
Fax Number:	(704)444-1111
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508382000
Email:	raquel.west@alston.com
Correspondent Name:	ALSTON & BIRD LLP
Address Line 1:	BANK OF AMERICA PLAZA
Address Line 2:	101 SOUTH TRYON STREET, SUITE 4000
Address Line 4:	CHARLOTTE, NORTH CAROLINA 28280-4000
ATTORNEY DOCKET NUMBER:	058522-480922
NAME OF SUBMITTER:	CINDY CHANG
SIGNATURE:	/Cindy Chang/
DATE SIGNED:	06/28/2018
Total Attachments: 2	
source=480922_Akari_2_Yisum#page1.tif	
source=480922_Akari_2_Yisum#page2.tif	

ASSIGNMENT

THIS ASSIGNMENT, by AKARI THERAPEUTICS, PLC, (Company registration number: 05252842), whose registered office is at 42-50 Hershaw Road, Walton-On-Thames, Surrey, United Kingdom, KT12 1RZ, (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, by virtue of an Assignment recorded in the United States Patent and Trademark Office, at reel and frame 025473/0496, the Assignor is the owner of an undivided right, title and interest in and to the invention set forth as follows:

Title of Invention: LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES THEREOF

US Application No.: 12/997,014

Filing Date: 12/09/2010

WHEREAS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. THE HEBREW UNIVERSITY OF JERUSALEM, a private limited company incorporated under the laws of Israel, and having its registered office at P.O. BOX 39135, Jerusalem, Israel 91390 (hereinafter referred to as "the Assignee"), has acquired the Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention, and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries, and any applications claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, without representation or warranty as to the patentability, validity, enforceability or commercial value of the above-mentioned invention and application, all of the Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention and the right, title and interest in and to any such applications, including provisional applications, and any applications claiming priority from said applications for Letters Patent of the United States or other countries, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the Paris Convention for the Protection of Industrial Property, including the right to claim priority, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made; AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with

said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts reasonably necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, Assignor has signed its name on the date indicated.


AKARI THERAPEUTICS, PLC

Date: November 2, 2016

By: _____

Name: Gur Roshwalb, M.D., MBA

Title: Chief Executive Officer



IN TESTIMONY WHEREOF, Assignee has signed its name on the date indicated.

YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW UNIVERSITY OF
JERUSALEM LTD. THE HEBREW UNIVERSITY
OF JERSUALEM


Date: November 6th, 2016

By: _____

Irina Abramzon-Shmueli
VP-Intellectual Property

Name: _____

Title: _____



Yissum Research Development Company
of the Hebrew University of Jerusalem Ltd.

LEGAL02/36673381v1